Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasgow Early Treatment Arm FavIpiravir: randomized controlled study of favipiravir as early treatment in COVID-19
2020-001904-41Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001904-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001904-41.